Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Kohan

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
European Journal of Preventive Cardiology|August 1, 2015
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersBauke Schievink, Dick de Zeeuw, Paul A Smink, et al.
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
The New England Journal of Medicine|November 3, 2023
Sparsentan versus Irbesartan in Focal Segmental GlomerulosclerosisMichelle N Rheault, Charles E Alpers, Jonathan Barratt, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
European Journal of Preventive Cardiology|August 1, 2015
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersBauke Schievink, Dick de Zeeuw, Paul A Smink, et al.
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
The New England Journal of Medicine|November 3, 2023
Sparsentan versus Irbesartan in Focal Segmental GlomerulosclerosisMichelle N Rheault, Charles E Alpers, Jonathan Barratt, et al.
Pageof 2